Cargando…
Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
A 71‐year‐old man was diagnosed with squamous cell lung carcinoma with high expression of programmed cell death ligand 1 (PDL1) (cT4N1M1b stage IVA). He was treated with pembrolizumab, but 14 days later, he suffered from pembrolizumab‐related retinal vasculitis as an immune‐related adverse event (ir...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938210/ https://www.ncbi.nlm.nih.gov/pubmed/33732464 http://dx.doi.org/10.1002/rcr2.730 |